Home » Stocks » Cyclo Therapeutics

Cyclo Therapeutics Inc. (CTDH)

Stock Price: $0.120 USD 0.000 (0.00%)
Updated Aug 14, 2020 4:00 PM EDT - End of day

Stock Price Chart

Key Info

Market Cap 17.00M
Revenue (ttm) 1.11M
Net Income (ttm) -8.26M
Shares Out 141.67M
EPS (ttm) -0.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $0.120
Previous Close $0.120
Change ($) 0.000
Change (%) 0.00%
Day's Open 0.127
Day's Range 0.116 - 0.135
Day's Volume 26,139
52-Week Range 0.080 - 0.440

More Stats

Market Cap 17.00M
Enterprise Value 16.04M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 141.67M
Float 74.32M
EPS (basic) -0.06
EPS (diluted) -0.07
FCF / Share -0.06
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta -0.47
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 15.29
PB Ratio 6.62
Revenue 1.11M
Operating Income -8.28M
Net Income -8.26M
Free Cash Flow -7.22M
Net Cash 955,802
Net Cash / Share 0.01
Gross Margin 69.21%
Operating Margin -744.43%
Profit Margin -742.90%
FCF Margin -649.59%
ROA -246.91%
ROE -338.60%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$1.25*
Low
1.25
Current: $0.120
High
1.25
Target: 1.25
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue1.011.011.241.500.951.571.691.041.030.80
Revenue Growth-0.42%-18.28%-17.64%58.13%-39.36%-7.43%62.05%1.27%28.6%-
Gross Profit0.930.911.101.300.831.291.270.910.760.69
Operating Income-7.54-4.27-3.84-4.21-2.41-0.560.340.16-0.07-0.01
Net Income-7.53-4.26-3.83-4.22-2.55-0.590.200.07-0.10-0.04
Shares Outstanding10881.7672.0463.3556.2150.5437.1736.6835.8133.71
Earnings Per Share-0.07-0.05-0.05-0.07-0.05-0.010.010.01-0.01-0.01
EPS Growth------0%---
Operating Cash Flow-6.59-3.19-3.06-2.95-1.99-0.630.560.060.190.21
Capital Expenditures---0.92-0.42-0.17-0.15-0.17-0.55-0.44
Free Cash Flow-6.59-3.19-3.06-2.04-2.41-0.810.40-0.11-0.37-0.23
Cash & Equivalents2.822.251.310.991.842.380.270.020.130.11
Total Debt0.02---0.740.790.850.990.840.44
Net Cash / Debt2.812.251.310.991.101.59-0.58-0.96-0.71-0.33
Assets4.112.922.091.874.745.292.792.622.791.93
Liabilities3.181.930.940.341.000.920.991.071.370.53
Book Value0.940.991.151.533.754.371.801.551.421.40
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Cyclo Therapeutics Inc.
Country United States
Employees 5
CEO Nathan Scott Fine

Stock Information

Ticker Symbol CTDH
Stock Exchange US OTC
Sector Healthcare
Industry Biotechnology
Unique Identifier OTCMKTS: CTDH

Description

Cyclo Therapeutics, Inc., a biotechnology company, develops cyclodextrin-based products for the treatment of diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Niemann-Pick Type C disease. The company also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. It has a collaboration with the Chattanooga Center for Neurologic Research. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in October 2019. Cyclo Therapeutics, Inc. was founded in 1990 and is based in Gainesville, Florida.